drugset / Trial / NCT05775575
A Clinical Trial of TQB3909 Tablets in Patients With Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
TQB3909 is an inhibitor targeting B-cell lymphoma (BCL)-2 protein. By binding to BCL-2 protein, TQB3909 releases Pro apoptotic proteins such as BCL-2-Anatagonist/Killer 1(BAK), BCL-2 associated X (BAX) protein and BCL-2 associated death (BAD) protein, promotes the release of cytochrome c from mitochondria, phosphatidylserine eversion, stimulates caspase 3/7 activity and caspase 3/9 cleavage, and induces apoptosis.
Timeline
- Start
- 2023-03-02
- Primary completion
- 2023-12
- Completion
- 2023-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TQB3909 | Unknown | 200 mg | Oral |
| Subject | TQB3909 | Unknown | 1000 mg | Oral |